A first-ever testosterone patch that would ‘significantly’ improve the lives of postmenopausal women by allowing them to regain their libido is undergoing clinical trials in the UK.
This ‘significant’ development will ‘give more choice’ to women, said Dr Haitham Hamoda, clinical manager of the menopause service at King’s College Hospital and former president of the British Menopause Society, according to what reported The Guardian Monday.
After menopause, testosterone production drops drastically in women, causing several effects, including a loss of libido.
While there are testosterone creams and gels available in some countries, these products are inconvenient, often designed for men and can transfer to clothing once applied to the skin.
If the clinical trial proves conclusive, it would be a first patch of testosterone, which is applied directly to the skin and only needs to be changed twice a week, which might counter certain symptoms of menopause.
“It might bring to market a necessary product that is simply not available [à l’heure actuelle]. With this proven technology, we will be able to eliminate unnecessary misery from the daily lives of women,” said University of Warwick Professor David Hiddleton.
The company he co-founded, Medherant, will begin clinical trials this fall.
